Reckitt Benckiser Pharmaceuticals will co-develop a unit-dose naloxone nasal spray for the reversal of opioid overdoses with Kentucky-based AntiOp, the company has announced. The only detail of the deal that was released is that the agreement includes an option for Reckitt Benckiser to acquire all marketing rights to the nasal spray if approved. Reckitt Benckiser … [Read more...] about Reckitt Benckiser to co-develop naloxone nasal spray
Business
Skyepharma provides updates on Flutiform
As part of an interim management statement, Skyepharma has said that the launch of its Flutiform fluticasone/formoterol MDI in Spain could take place by the end of 2014, triggering a milestone payment of €2.0 million. The company also noted that it has received a €3.0 million milestone payment for the launch of the product in France in the first quarter of 2014. In … [Read more...] about Skyepharma provides updates on Flutiform
FDA approves Apotex’s generic budesonide nasal spray
Apotex says that it launched a generic budesonide nasal spray in the US on May 13, 2014 following the previous day's approval of the product by the FDA. The new product, with a strength of 32 mcg/spray, is a generic equivalent for AstraZeneca's Rhinocort Aqua. Apotex's suggested average wholesale price is $160.53, which appears to be similar to the retail price of … [Read more...] about FDA approves Apotex’s generic budesonide nasal spray
FDA approves Perrigo’s azelastine nasal spray
Perrigo has announced that it has begun shipping its generic version of Astepro azelastine nasal spray after the ANDA it submitted in partnership with Impax Laboratories received final approval from the FDA. In January 2012, after the two companies filed the ANDA, Astepro maker Meda Pharmaceuticals filed suit for patent infringement in US District Court. According to … [Read more...] about FDA approves Perrigo’s azelastine nasal spray
Philips-Medisize to be acquired by Golden State Capital
Device manufacturer Phillips-Medisize has announced that it will be acquired by Golden Gate Capital for an undisclosed amount. According to the announcement, Matt Jennings will remain as President and CEO, and the company will keep its headquarters in Wisconsin. The company, which offers design and manufacturing services for medical devices, including inhalers, has … [Read more...] about Philips-Medisize to be acquired by Golden State Capital
New patents for Discovery Labs’ aerosol surfactant and delivery system
Discovery Laboratories has announced that the US Patent and Trademark Office (USPTO) has issued the company a new patent titled "Ventilation Circuit Adaptor and Proximal Aerosol Delivery System" (Patent No. 8,701,658) and Notices of Allowance for two patents titled "Lyophilization of Synthetic Liposomal Pulmonary Surfactant" (application nos.14/091,608 and … [Read more...] about New patents for Discovery Labs’ aerosol surfactant and delivery system
3M DDS to expand UK MDI facility
According to 3M Drug Delivery Systems, the company will increase the capacity of its Loughborough, UK MDI facility by more than 20%. No additional details were provided. 3M DDS VP of Inhalation Drug Delivery Marcello Napol said, “Since developing the first MDI almost 60 years ago, 3M has continued pioneering in inhalation drug delivery, and this expansion of our … [Read more...] about 3M DDS to expand UK MDI facility
Bayer acquires Afrin nasal spray
Merck has announced the sale of its Consumer Care division, which markets Afrin oxymetazoline nasal spray, to Bayer. According to Bayer, "The purchase price of USD 14.2 billion includes a payment associated with sales of Claritin and Afrin in certain countries where these products are still prescription-only." Bayer Chairman Marijn Dekkers cited Afrin as one of … [Read more...] about Bayer acquires Afrin nasal spray
Survey says US payers would pay more for treatment that reduces asthma exacerbations
Decision Resources Group says that a survey of US payers found that 90 percent said they would pay a premium for a new treatment that does a significantly better job of reducing asthma exacerbations than Xolair (omalizumab). The survey results are in a report titled "Asthma (Moderate to Severe): Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do … [Read more...] about Survey says US payers would pay more for treatment that reduces asthma exacerbations
Medivir launches Adasuve in four Nordic countries
Medivir has announced the launch of Adasuve inhaled loxapine for the treatment of agitation in schizophrenic or bipolar patients in Sweden, Norway, Finland, and Denmark. Medivir acquired the rights to commercialize Adasuve in all five Nordic countries from Grupo Ferrer in September 2013. Medivir Executive VP, Commercial, Henrik Krook, commented, “It is gratifying … [Read more...] about Medivir launches Adasuve in four Nordic countries